Summary
Hematopoietic stem cells (HSC) are inherently rare cell types that cannot be obtained in sufficient amounts for classical biochemical characterization. To facilitate functional studies of murine HSC and hematopoietic development, the technique of retroviral-mediated gene transfer provides a useful tool. The generation of high titer retroviral vectors permits transduction of stem cells with a variety of genes and leads to long-term marking in the blood of recipient mice. Optimized promoter/enhancers facilitate high-level transgene expression in mice transplanted with transduced bone marrow (BM) cells. The co-expression of reporter genes along with a gene of interest greatly facilitates tracking donor engraftment of transduced hematopoietic progeny following stem cell transplantation. This methodology can be used to reconstitute defective function in a mutant background or to study protein function during hematopoiesis by overexpression. Despite limitations such as integration site variegation and copy number-dependent effects, this approach is rapid and efficient compared with transgenic mouse technology. In this chapter, we review this broadly applicable technique for achieving high-level murine BM stem cell transduction. We also describe methods for transplantation and subsequent analysis of transplanted mice as a bona fide assay for the stem cell transduction efficiency.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Nienhuis A. W., Walsh C. E., and Liu J. Viruses as therapeutic gene transfer vectors. In: Young N. S., ed. (1993) Viruses and Bone Marrow: Basic Research and Clinical Practice. New York: Dekker, 353–414.
Markowitz, D., Goff, S., and Bank, A. (1988) Construction and use of a safe and efficient amphotropic packaging cell line. Virology 167, 400–406.
Markowitz, D. G., Goff, S. P., and Bank, A. (1988) Safe and efficient ecotropic and amphotropic packaging lines for use in gene transfer experiments. Trans. Assoc. Am. Physicians 101, 212–218.
Miller, A. D. (1990) Retrovirus packaging cells. Hum. Gene Ther. 1, 5–14.
Kohno, T., Mohan, S., Goto, T., Morita, C., Nakano, T., Hong, W., Sangco, J. C., Morimatsu, S., and Sano, K. (2002) A new improved method for the concentration of HIV-1 infective particles. J. Virol. Methods 106, 167–173.
Baum, C., Dullmann, J., Li, Z., Fehse, B., Meyer, J., Williams, D. A., and von Kalle, C. (2003) Side effects of retroviral gene transfer into hematopoietic stem cells. Blood 101, 2099–2114.
Philippe, S., Sarkis, C., Barkats, M., Mammeri, H., Ladroue, C., Petit, C., Mallet, J., and Serguera, C. (2006) Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 103, 17684–17689.
Martin, P., Albagli, O., Poggi, M. C., Boulukos, K. E., and Pognonec, P. (2006) Development of a new bicistronic retroviral vector with strong IRES activity. BMC. Biotechnol. 6, 4.
Klump, H., Schiedlmeier, B., Vogt, B., Ryan, M., Ostertag, W., and Baum, C. (2001) Retroviral vector-mediated expression of HoxB4 in hematopoietic cells using a novel coexpression strategy. Gene Ther. 8, 811–817.
Amendola, M., Venneri, M. A., Biffi, A., Vigna, E., and Naldini, L. (2005) Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters. Nat. Biotechnol. 23, 108–116.
Zaboikin, M., Srinivasakumar, N., and Schuening, F. (2006) Gene therapy with drug resistance genes. Cancer Gene Ther. 13, 335–345.
Milsom, M. D., Fairbairn, L. J. (2004) Protection and selection for gene therapy in the hematopoietic system. J. Gene Med. 6, 133–146.
Flasshove, M., Moritz, T., Bardenheuer, W., and Seeber, S. (2003) Hematoprotection by transfer of drug-resistance genes. Acta Haematol. 110, 93–106.
Persons, D. A., Allay, J. A., Allay, E. R., Smeyne, R. J., Ashmun, R. A., Sorrentino, B. P., and Nienhuis, A. W. (1997) Retroviral-mediated transfer of the green fluorescent protein gene into murine hematopoietic cells facilitates scoring and selection of transduced progenitors in vitro and identification of genetically modified cells in vivo. Blood 90, 1777–1786.
Hawley, T. S., Telford, W. G., and Hawley, R. G. (2001) “Rainbow” reporters for multispectral marking and lineage analysis of hematopoietic stem cells. Stem Cells 19, 118–124.
Persons, D. A., Allay, J. A., Riberdy, J. M., Wersto, R. P., Donahue, R. E., Sorrentino, B. P., and Nienhuis, A. W. (1998) Use of the green fluorescent protein as a marker to identify and track genetically modified hematopoietic cells. Nat. Med. 4, 1201–1205.
Dick, J. E., Magli, M. C., Huszar, D., Phillips, R. A., and Bernstein, A. (1985) Introduction of a selectable gene into primitive stem cells capable of long-term reconstitution of the hemopoietic system of W/Wv mice. Cell 42, 71–79.
Szilvassy, S. J., Fraser, C. C., Eaves, C. J., Lansdorp, P. M., Eaves, A. C., and Humphries, R. K. (1989) Retrovirus-mediated gene transfer to purified hemopoietic stem cells with long-term lympho-myelopoietic repopulating ability. Proc. Natl. Acad. Sci. U.S.A. 86, 8798–8802.
Fraser, C. C., Szilvassy, S. J., Eaves, C. J., and Humphries, R. K. (1992) Proliferation of totipotent hematopoietic stem cells in vitro with retention of long-term competitive in vivo reconstituting ability. Proc. Natl. Acad. Sci. U.S.A. 89, 1968–1972.
Hawley, R. G., Lieu, F. H., Fong, A. Z., and Hawley, T. S. (1994) Versatile retroviral vectors for potential use in gene therapy. Gene Ther. 1, 136–138.
Bunting, K. D., Galipeau, J., Topham, D., Benaim, E., and Sorrentino, B. P. (1998) Transduction of murine bone marrow cells with an MDR1 vector enables ex vivo stem cell expansion, but these expanded grafts cause a myeloproliferative syndrome in transplanted mice. Blood 92, 2269–2279.
Sorrentino, B. P., McDonagh, K. T., Woods, D., and Orlic, D. (1995) Expression of retroviral vectors containing the human multidrug resistance 1 cDNA in hematopoietic cells of transplanted mice. Blood 86, 491–501.
Allay, J. A., Dumenco, L. L., Koc, O. N., Liu, L., and Gerson, S. L. (1995) Retroviral transduction and expression of the human alkyltransferase cDNA provides nitrosource resistance to hematopoietic cells. Blood 85, 3342–3351.
Allay, J. A., Davis, B. M., and Gerson, S. L. (1997) Human alkyltransferase-transduced murine myeloid progenitors are enriched in vivo by BCNU treatment of transplanted mice. Exp. Hematol. 25, 1069–1076.
Corey, C. A., DeSilva, A. D., Holland, C. A., and Williams, D. A. (1990) Serial transplantation of methotrexate-resistant bone marrow: protection of murine recipients from drug toxicity by progeny of transduced stem cells. Blood 75, 337–343.
Zhao, S. C., Li, M. X., Banerjee, D., Schweitzer, B. I., Mineishi, S., Gilboa, E., and Bertino, J. R. (1994) Long-term protection of recipient mice from lethal doses of methotrexate by marrow infected with a double-copy vector retrovirus containing a mutant dihydrofolate reductase. Cancer Gene Ther. 1, 27–33.
Allay, J. A., Galipeau, J., Blakley, R. L., and Sorrentino, B. P. (1998) Retroviral vectors containing a variant dihydrofolate reductase gene for drug protection and in vivo selection of hematopoietic cells. Stem Cells 16 Suppl 1, 223–233.
Matsunaga, T., Sakamaki, S., Kuga, T., Kuroda, H., Kusakabe, T., Akiyama, T., Konuma, Y., Hirayama, Y., Kobune, M., Kato, J., Sasaki, K., Kogawa, K., Koyama, R., and Niitsu, Y. (2000) GST-pi gene-transduced hematopoietic progenitor cell transplantation overcomes the bone marrow toxicity of cyclophosphamide in mice. Hum. Gene Ther. 11, 1671–1681.
Momparler, R. L., Eliopoulos, N., Bovenzi, V., Letourneau, S., Greenbaum, M., and Cournoyer, D. (1996) Resistance to cytosine arabinoside by retrovirally mediated gene transfer of human cytidine deaminase into murine fibroblast and hematopoietic cells. Cancer Gene Ther. 3, 331–338.
Rattmann, I., Kleff, V., Sorg, U. R., Bardenheuer, W., Brueckner, A., Hilger, R. A., Opalka, B., Seeber, S., Flasshove, M., and Moritz, T. (2006) Gene transfer of cytidine deaminase protects myelopoiesis from cytidine analogs in an in vivo murine transplant model. Blood 108, 2965–2971.
Flasshove, M., Frings, W., Schroder, J. K., Moritz, T., Schutte, J., and Seeber, S. (1999) Transfer of the cytidine deaminase cDNA into hematopoietic cells. Leuk. Res. 23, 1047–1053.
Magni, M., Shammah, S., Schiro, R., Mellado, W., la-Favera, R., and Gianni, A. M. (1996) Induction of cyclophosphamide-resistance by aldehyde-dehydrogenase gene transfer. Blood 87, 1097–1103.
Bunting, K. D., Townsend, A. J. (1996) Protection by transfected rat or human class 3 aldehyde dehydrogenase against the cytotoxic effects of oxazaphosphorine alkylating agents in hamster V79 cell lines. Demonstration of aldophosphamide metabolism by the human cytosolic class 3 isozyme. J. Biol. Chem. 271, 11891–11896.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Humana Press, a part of Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Haviernik, P., Zhang, Y., Bunting, K.D. (2008). Retroviral Transduction of Murine Hematopoietic Stem Cells. In: Bunting, K.D. (eds) Hematopoietic Stem Cell Protocols. Methods in Molecular Biology™, vol 430. Humana Press. https://doi.org/10.1007/978-1-59745-182-6_16
Download citation
DOI: https://doi.org/10.1007/978-1-59745-182-6_16
Publisher Name: Humana Press
Print ISBN: 978-1-58829-868-3
Online ISBN: 978-1-59745-182-6
eBook Packages: Springer Protocols